Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022
eLife · 2025
DOI: 10.7554/elife.94475 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Lucia Inchauste und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unité des Virus Émergents, Marseille, France. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Blood Donors, Antibodies, Viral. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Institute for Sustainable Development, ANRS MIE, Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Background
Unlike genomic data, serological data have not been previously leveraged to evaluate the SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were lacking, especially at the beginning of the pandemic.
Methods
In 2021 and 2022 we estimated the prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the feasibility of using virus serum neutralization data for variants thought to have circulated to map their circulation across all departments over a year-long follow-up period. Anti-S1 and anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2.
Results
Between 2021 and 2022, the overall prevalence of anti-S1 and anti-NCP antibodies increased, reaching values over 90%, demonstrating that a large proportion of the Bolivian population was no longer naïve to the virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma continued to circulate in southernmost departments of the country, and the emergence of Omicron BA.1 was detected. These trends align with publicly available genomic data from neighboring countries.
Conclusions
Our serological analyses successfully identified both new antigenic groups, such as Omicron BA.1, and individual variants related to previously circulating groups, such as Delta. The study contributes insights into overall population immunity to SARS-CoV-2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes the potency of seroprevalence studies in informing public health decisions and underscores their value in capturing the initial phases of emerging epidemics when variant diversity is limited, facilitating timely genomic surveillance setup. Funding: This study was supported by the French National Research Institute for Sustainable Development (IRD), the project EMERGEN-PRI #22275 of the ANRS I MIE (INSERM), and the European Union’s Horizon 2020 research and innovation program (European Virus Archive Global, grant agreement No. 871029). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unité des Virus Émergents, Marseille, France.
- Programa Nacional de Sangre, Ministerio de Salud y Deportes, La Paz, Bolivia.
- Banco de Sangre de Referencia Departmental de Beni, Beni, Bolivia.
- Banco de Sangre de Referencia Departmental de Chuquisaca, Sucre, Bolivia.
- Banco de Sangre de Referencia Departmental de Cochabamba, Cochabamba, Bolivia.
- Banco de Sangre de Referencia Departmental de El Alto, El Alto, Bolivia.
ORCID-Profile: Stéphane Priet
Förderung
- French National Research Institute for Sustainable Development
- ANRS MIE
- Horizon 2020 Framework Programme
Zitieren
APA
Inchauste, L., Nurtop, E., Bautista Machicado, L., Leigue Roth, Y., Lenz Gonzales, S., Herrera, M. L., Mina Villafan, K., Mamani Mamani, P., Ramos Espinoza, M., Pavel Suarez, J. C., Garcia Copa, J. C., Leigue Zabala, Y., Arancibia Cardozo, E., Gallian, P., de Lamballerie, X., & Priet, S. (2025). Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022. eLife. https://doi.org/10.7554/elife.94475
Vancouver
Inchauste L, Nurtop E, Bautista Machicado L, Leigue Roth Y, Lenz Gonzales S, Herrera ML, et al. Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022. eLife. 2025. doi:10.7554/elife.94475
BibTeX
@article{Inchauste2025,
author = {Inchauste, Lucia and Nurtop, Elif and Bautista Machicado, Lissete and Leigue Roth, Yanine and Lenz Gonzales, Shirley and Herrera, Maria Luisa and Mina Villafan, Katty and Mamani Mamani, Pedro and Ramos Espinoza, Marcelo and Pavel Suarez, Juan Carlos and Garcia Copa, Juan Cansio and Leigue Zabala, Yitzhak and Arancibia Cardozo, Etzel and Gallian, Pierre and de Lamballerie, Xavier and Priet, Stéphane},
title = {Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.94475}
}
EUVIMED